Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

PCC100C01

Millipore

Pellicon® Capsule with Ultracel® Membrane

pore size 100 kDa, C Screen, 0.1 m2

Synonym(s):

Pellicon® Capsule with Ultracel® Membrane

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41104903
Pricing and availability is not currently available.

material

EPDM rubber seal
PPO/PS blend (core)
PPO/PS blend housing
TPE seal
composite regenerated cellulose (CRC) membrane
epoxy adhesive
polyester screen
polypropylene screen
polyurethane adhesive

Quality Level

400

sterility

sterile; γ-irradiated

product line

Pellicon®

storage condition

room temperature (15-30°C)

parameter

4-6 L/min-m2 flow rate
45 psi max. transmembrane pressure (3.1 bar) at 4-30 °C (Forward)
80 psi max. inlet pressure (5.5 bar) at 4 - 30 °C

technique(s)

ultrafiltration: suitable

L

35.3 cm (13.9 in.)

diam.

3.8 cm (1.5 in.)

filtration area

0.1 m2

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PCC300C01PCC100C05PCC300C05
Pellicon® Capsule with Ultracel® Membrane pore size 100 kDa, C Screen, 0.1 m2

PCC100C01

Pellicon® Capsule with Ultracel® Membrane

Pellicon® Capsule with Ultracel® Membrane pore size 300 kDa, C Screen, 0.1 m2

PCC300C01

Pellicon® Capsule with Ultracel® Membrane

Pellicon® Capsule with Ultracel® Membrane pore size 100 kDa, C Screen, 0.5 m2

PCC100C05

Pellicon® Capsule with Ultracel® Membrane

Pellicon® Capsule with Ultracel® Membrane pore size 300 kDa, C Screen, 0.5 m2

PCC300C05

Pellicon® Capsule with Ultracel® Membrane

pore size

100 kDa

pore size

300 kDa

pore size

100 kDa

pore size

300 kDa

filtration area

0.1 m2

filtration area

0.1 m2

filtration area

0.5 m2

filtration area

0.5 m2

technique(s)

ultrafiltration: suitable

technique(s)

ultrafiltration: suitable

technique(s)

ultrafiltration: suitable

technique(s)

ultrafiltration: suitable

product line

Pellicon®

product line

Pellicon®

product line

Pellicon®

product line

Pellicon®

sterility

sterile; γ-irradiated

sterility

sterile; γ-irradiated

sterility

sterile; γ-irradiated

sterility

sterile; γ-irradiated

fitting

inlet/outlet connection (Feed: 3/4" Sanitary Flange), inlet/outlet connection (Retentate: 3/4" Sanitary Flange), inlet/outlet connection (Permeate: 3/4" Sanitary Flange)

fitting

inlet/outlet connection (Feed: 3/4" Sanitary Flange), inlet/outlet connection (Permeate: 3/4" Sanitary Flange), inlet/outlet connection (Retentate: 3/4" Sanitary Flange)

fitting

inlet/outlet connection (Feed: 3/4" Sanitary Flange), inlet/outlet connection (Permeate: 3/4" Sanitary Flange), inlet/outlet connection (Retentate: 3/4" Sanitary Flange)

fitting

inlet/outlet connection (Feed: 3/4" Sanitary Flange), inlet/outlet connection (Permeate: 3/4" Sanitary Flange), inlet/outlet connection (Retentate: 3/4" Sanitary Flange)

General description

The Pellicon® Capsule is the first of its kind -- a true single-use TFF device that comes ready to process in minutes. Self-contained, it employs an easy-to-use, holderless format and is supplied sterilized by irradiation.

Application

Viral Gene Therapies, Vaccines, Concentration, Diafiltration, Buffer exchange, Protein purification, mRNA

Features and Benefits

Plug ′n play, holderless design - easy to install, safe to remove
Gamma sterilized and preservative-free - ready to process in minutes
True single-use, self-contained capsule - fast, safe, and flexible batch turnaround
Proven Ultracel® membrane and C screen - high recovery, superior mass transfer, solvent resistance
Pellicon® TFF proven performance - true linear scalability within Pellicon® TFF families

Packaging

A foam clamshell is inserted over the end caps on both ends of the capsule which is then double-bagged and vacuum sealed. The double-bagged capsule is placed on a tray and then individually boxed.

Other Notes

The Emprove® Program complements the product portfolio through

Comprehensive documentation to support qualification, risk assessment and process optimization needs.
Consolidation of product specific testing, quality and regulatory information to simplify compliance requirements.
Convenient 24/7 access to up-to-date product information.

Legal Information

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany
Pellicon is a registered trademark of Merck KGaA, Darmstadt, Germany
ULTRACEL is a registered trademark of Merck KGaA, Darmstadt, Germany

    • Certificates of Analysis (COA)

    Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Jinxiang Yuan et al.
    Journal of virology, 89(24), 12284-12298 (2015-10-02)
    Triggers and regulatory pathways that effectively link human cytomegalovirus (HCMV) major immediate early (MIE) latent-lytic switch activation with progeny production are incompletely understood. In the quiescently infected human NTera2 cell model of primitive neural stem cells, we found that costimulation
    Ganna Galitska et al.
    Frontiers in immunology, 12, 532484-532484 (2021-04-27)
    Human cytomegalovirus (HCMV) infection often leads to systemic disease in immunodeficient patients and congenitally infected children. Despite its clinical significance, the exact mechanisms contributing to HCMV pathogenesis and clinical outcomes have yet to be determined. One of such mechanisms involves
    Melissa Galinato et al.
    Frontiers in microbiology, 10, 577-577 (2019-04-06)
    Myeloid cells are important sites of lytic and latent infection by human cytomegalovirus (CMV). We previously showed that only a small subset of myeloid cells differentiated from CD34+ hematopoietic stem cells is permissive to CMV replication, underscoring the heterogeneous nature
    Ramona Businger et al.
    mBio, 12(4), e0177021-e0177021 (2021-08-18)
    The plasma membrane (PM) must be overcome by viruses during entry and release. Furthermore, the PM represents the cellular communication compartment and the immune system interface. Hence, viruses have evolved sophisticated strategies to remodel the PM, for instance to avoid
    Ozan S Kumru et al.
    Vaccine, 37(44), 6696-6706 (2019-09-25)
    Live attenuated viral vaccine/vector candidates are inherently unstable and infectivity titer losses can readily occur without defining appropriate formulations, storage conditions and clinical handling practices. During initial process development of a candidate vaccine against HIV-1 using a recombinant Human Cytomegalovirus
    View All Related Papers

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service